House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Haematology

Neutropenic sepsis: prevention and management in people with cancer

NICE · 2012 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE CG151 treats suspected neutropenic sepsis during anticancer treatment as an emergency. It covers prevention, recognition, immediate antibiotics, confirmation and risk-guided follow-up in adults and children. Adult-only prevention recommendations are distinguished from the all-age acute-care pathway. The reviewed recommendations include the later fluoroquinolone safety notice; microbiology, patient-specific contraindications and social circumstances remain part of treatment decisions.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Prepare patients and reduce infection risk

  • Before and throughout anticancer treatment, give patients and carers written and verbal information about neutropenic sepsis, access to specialist oncology advice around the clock, and when to seek emergency care. Train staff according to their contact with these patients. [1]
  • For adults aged ≥18 with acute leukaemia, stem-cell transplantation or solid tumours and anticipated chemotherapy-related neutrophils ≤0.5 × 10^9/L, offer fluoroquinolone prophylaxis only during the expected neutropenic period. [1]
  • Apply the linked restrictions and precautions for fluoroquinolones, including the risk of disabling and potentially long-lasting or irreversible adverse effects. Monitor resistance and infection patterns in facilities using prophylaxis. [1]
  • Do not routinely give G-CSF to prevent neutropenic sepsis in adults on chemotherapy, except when it is integral to the regimen or needed to maintain dose intensity. [1]

Recognize and assess the emergency

  • Suspect neutropenic sepsis whenever someone receiving anticancer treatment becomes unwell. Refer immediately to secondary or tertiary care, and give empiric antibiotics immediately as part of emergency treatment. [1]
  • Initial assessment includes history, examination, full blood count, renal and liver tests including albumin, CRP, lactate and blood culture. [1]
  • After initial assessment, seek the underlying cause. Obtain an additional peripheral blood culture in patients with a central venous device if feasible, and perform urinalysis in children under 5. Do chest radiography only when clinically indicated. [1]
  • Confirm neutropenic sepsis during anticancer treatment when neutrophils are ≤0.5 × 10^9/L together with either temperature >38°C or other signs or symptoms of clinically significant sepsis. Fever is therefore not mandatory when the other clinical criterion is present. [1]

Select initial empiric antibiotics

  • For patients requiring intravenous treatment, use piperacillin–tazobactam monotherapy initially unless patient-specific factors or local microbiology contraindicate it. [1]
  • Do not add or substitute an aminoglycoside for initial empiric treatment without a patient-specific or local microbiological indication. A central venous device alone does not justify empiric glycopeptide treatment. [1]
  • Do not remove a central venous access device as part of initial empiric management. [1]

Reassess risk and determine the place of care

  • Within 24 hours of hospital presentation, a professional competent in anticancer-treatment complications should assess septic-complication risk using presentation features and a validated score. [1]
  • For confirmed low-risk neutropenic sepsis, consider outpatient antibiotics after reviewing clinical and social circumstances and explaining the need to return promptly if problems develop. Review high-risk patients daily and repeat a validated risk assessment. [1]
  • After 48 hours, switch from intravenous to oral antibiotics only after a competent professional has reassessed complication risk as low with a validated score. [1]
  • Discharge during empiric antibiotic treatment requires reassessment as low risk using a validated score, consideration of clinical and social circumstances, and clear advice to return promptly if a problem occurs. [1]

Base changes and duration on response

  • Persistent fever alone is not a reason to change the initial empiric antibiotics: change them for clinical deterioration or a microbiological indication. Continue inpatient empiric treatment for unresponsive fever unless an alternative cause is likely. [1]
  • When neutropenic sepsis has responded to treatment, discontinue empiric antibiotic therapy irrespective of the neutrophil count. [1]

Limitations and use

  • Drug doses, allergy alternatives and detailed organism-directed treatment are not specified in this recommendation chapter. Local microbiology and patient-specific contraindications are explicit qualifications.
  • The source’s licensing statements refer to the UK and to stated historical dates; they are not current Indian licensing determinations. The fluoroquinolone notice refers to serious adverse effects and prescribing restrictions.
  • Risk scores support assessment but do not replace the required clinical and social review. Immediate treatment of suspected sepsis should not await the confirmatory neutrophil result.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Neutropenic sepsis: prevention and management in people with cancer

    Guideline recommendation text consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
19 September 2012
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Prepare patients and reduce infection risk
  • Recognize and assess the emergency
  • Select initial empiric antibiotics
  • Reassess risk and determine the place of care
  • Base changes and duration on response
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House